Provectus Biopharmaceuticals Announces Poster Presentation on PV-10 for Melanoma at European Society for
Medical Oncology 2016 Congress
Poster Presentation Scheduled for October 9, 2016
Congress Scheduled to Run October 7-11, 2016, Copenhagen, Denmark
Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, www.provectusbio.com), a clinical-stage oncology and dermatology biopharmaceutical company ("Provectus" or “The
Company”), today announced that a poster presentation titled “Intralesional rose bengal for stage III and IV melanoma” is to be
presented at the European Society for Medical Oncology 2016 Congress on October 9, 2016, in Hall E of the Bella Center in
Copenhagen, Denmark.
ESMO’s Scientific Committee accepted the abstract for this poster presentation and further details can be found at https://cslide.ctimeetingtech.com/library/esmo/browse/search/CKJ - 2z95v (Abstract 1158TiP).
In addition, the abstract will be published in the ESMO 2016 Congress Abstract Book, a supplement to the official ESMO
journal, Annals of Oncology. ESMO has not yet announced the final publication number. The ESMO 2016 Congress will be held in
Copenhagen, Denmark, from October 7-11, 2016.
Provectus believes the poster itself will be available online following the final session of the Congress.
About ESMO
ESMO is the leading European professional organization for medical oncology. With more than 13,000 members representing oncology
professionals from over 130 countries, ESMO is the society of reference for oncology education and information. For more
information, visit: http://www.esmo.org/
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer.
Provectus’ investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers. The
Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its
topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has
completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis
and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information
about Provectus, please visit the Company's website at www.provectusbio.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains "forward-looking statements" as defined under U.S. federal securities laws.
These statements reflect management's current knowledge, assumptions, beliefs, estimates, and expectations and express management's
current views of future performance, results, and trends and may be identified by their use of terms such as "anticipate,"
"believe," "could," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," and other similar terms.
Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking
statements include those discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A
of our Annual Report on Form 10-K for the year ended December 31, 2015) and the following:
- our determination, based on guidance from the FDA, whether to proceed with or without a partner with
the fully enrolled phase 3 trial of PV-10 to treat locally advanced cutaneous melanoma and the costs associated with such a trial
if it is necessary to complete (versus interim data alone);
- our determination whether to license PV-10, our investigational drug product for melanoma and other
solid tumors such as cancers of the liver, if such licensure is appropriate considering the timing and structure of such a
license, or to commercialize PV-10 on our own to treat melanoma and other solid tumors such as cancers of the liver;
- our ability to license PH-10, our investigational drug product for dermatology, on the basis of our
phase 2 atopic dermatitis and psoriasis results, which are in the process of being further developed in conjunction with
mechanism of action studies; and
- our ability to raise additional capital if we determine to commercialize PV-10 and/or PH-10 on our
own, although our expectation is to be acquired by a prospective pharmaceutical or biotech concern prior to
commercialization.
Provectus Biopharmaceuticals, Inc.
Peter R. Culpepper, 866-594-5999 #30
Interim CEO, COO
or
Porter, LeVay & Rose, Inc.
Marlon Nurse, 212-564-4700
DM, SVP – Investor Relations
or
Allison + Partners
Todd Aydelotte, 646-428-0644
Managing Director – Media Relations
View source version on businesswire.com: http://www.businesswire.com/news/home/20160801005347/en/